knowledge -WSS

knowledge

author：comprehensive 2025-09-05 06:02:49 - browse：11

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Readout Newsletter: What happened with Sarepta's Duchenne data

focus

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

CDC picks Alphabet's Verily for wasterwater surveillance contract

Testing for cancer recurrence creates a new limbo for patients

IVG is promising — but it won’t replace IVF quite yet

The stability of $0 premiums in Medicare Advantage

Chimpanzees, like humans and whales, get menopause: Study

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Lawsuit highlights wrinkle for disputes over surprise medical bills

Guidelines to prevent youth baseball injuries need more muscle

Meta's Zuckerberg and Chan on track to put $50 billion into science

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: What happened with Sarepta's Duchenne data

Dobbs anniversary: the lost opportunity of abortion as health care

Telehealth options flood the market as retailers push virtual care

New air purifier tech could be key to improving indoor air quality

The FDA weighs the risks of candy

focus

Setback for rare diseases as Taysha Gene Therapies pulls back

CRISPR base editing slashes cholesterol levels in monkeys

Biden's order seeks to regulate AI risk without stifling innovation

Emergency medicine has repudiated 'excited delirium.' Now what?

6 solutions to address cancer drug shortages and others

Will an HIV vaccine ever be a reality?

leisure time

focus

knowledge

leisure time